No Data
No Data
Jiuzhou Pharmaceutical (603456): Annual revenue and profit growth slowed, CDMO business achieved high-quality growth
Announcement: Jiuzhou Pharmaceutical released its 2023 annual report. Comment: Revenue side growth is slowing down. In 2023, the company's revenue was 5.523 billion yuan, up 1.44% year on year; net profit to mother was 1,033 billion yuan, up 12 years on year
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved steady growth; 2) capacity building for new businesses such as peptides, conjugated drugs, and formulation platforms is beginning to bear fruit. (Mainichi Keizai Shimbun)
Jiuzhou Pharmaceutical (603456.SH): Japanese CRO mainly focuses on innovative drug CMC business
Gelonghui, April 16 | Jiuzhou Pharmaceutical (603456.SH) said on the investor interactive platform that Japan's CRO company mainly focuses on innovative drug CMC business and is expected to be put into use in the third quarter of 2024.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Analysts Just Slashed This Year's Estimates
The analysts covering Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for thi
Jiuzhou Pharmaceutical (603456): CDMO business is growing steadily, APIs are under pressure in the short term
Incident: The company announced its 2023 annual report. In 2023, it achieved operating income of 5.523 billion yuan (+1.44%), net profit to mother of 1,033 billion yuan (+12.17%), net profit not attributable to mother of 10.2 billion yuan
Jiuzhou Pharmaceutical (603456): CDMO is growing steadily and the API business is under pressure in the short term
Core idea The company's CDMO sector achieved steady growth of 19.4% in 2023, the number of pipeline projects continued to increase, and the number of commercialized projects reached 32. Although the API sector was under pressure in the short term due to increased competition in the industry, the company accelerated its push
No Data